Biotechnology specialists stress that research with a real-world impact is key to the field.

Biotech remains one of the market's more out-of-favor sectors despite improving industry fundamentals. Here are three stocks trading near multiyear lows.

One of the top fundraisers of 2024 is halving its workforce about a year after drawing in a $325 million series C. Cell therapy biotech Arsenal Biosciences has laid off about 50% of its staff as it ...

Though funding totals represented the highest first-half sum since the start of 2022, industry watchers are concerned that ...

Biotechnology companies are coming out of a dark period for the industry. Why has the tide turned and is now a good time to ...

Discover Prague's biotech hub, now viewed as the primary ‘entry gateway’ into the wider Central and Eastern European ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Behind the scenes of Southern ...

Healthcare and biotech stocks have had a rough run since the giddy heights of the Covid pandemic. But now could be the perfect time to consider investing in these beaten-down but high-growth sectors.